Floatz logo

Gfb-024

Endocrine System Diseases

Goldfinch Bio, Inc.Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Endocrine System Diseases cohort.

Asset / SponsorPhaseRating
Hcg
Merck KGaA, Darmstadt, Germany
Phase 3BB
TESTOSTERONE UNDECYLATE
Craig Hospital
Phase 4BB
Follitropin Alpha
Merck KGaA, Darmstadt, Germany
Phase 3BB
Msj-0011
Merck KGaA, Darmstadt, Germany
Phase 3BB
Irinotecan
Xiaoxiang Chen
Phase 2BB

View all 27 →

Same molecule, other indications

Gfb-024 is also rated in:

kidney disorderDormant
CC
Indicative ·
47 / 100
View asset →
diabetic kidney diseaseDormant
CC
Indicative ·
47 / 100
View asset →
Diabetes ComplicationsDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →